Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Why thrombin generation? From bench to bedside.

Louis M Aledort1

  • 1Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029-6574, USA. louis.aledort@mssm.edu

Pathophysiology of Haemostasis and Thrombosis
|July 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emicizumab in Hemophilia A. Reply.

The New England journal of medicine·2020
Same author

Deaths Associated with Emicizumab in Patients with Hemophilia A.

The New England journal of medicine·2019
Same author

The ongoing imperative for immune tolerance induction in inhibitor management.

Haemophilia : the official journal of the World Federation of Hemophilia·2019
Same author

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

The New England journal of medicine·2017
Same author

Treatment of Congenital Thrombotic Thrombocytopenia Purpura: A New Paradigm.

Journal of pediatric hematology/oncology·2017
Same author

A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.

Blood·2014

Laboratory tests for thrombin generation can help manage costly clotting and bleeding disorders. These tests offer a needed tool to define treatment regimens and improve patient safety by navigating the narrow margin between hemostasis and thrombosis.

Area of Science:

  • Biochemistry
  • Hematology
  • Pharmacology

Background:

  • Managing clotting and bleeding disorders presents significant costs and lacks defined treatment guidelines.
  • The narrow therapeutic window between achieving hemostasis and preventing thrombosis is difficult to predict.
  • There is a critical need for laboratory tests to guide treatment and assess therapeutic interventions.

Purpose of the Study:

  • To highlight the need for laboratory tests in managing hemostatic and thrombotic disorders.
  • To introduce thrombin generation as a valuable tool for this purpose.
  • To address the challenges in defining safe and effective therapeutic regimens.

Main Methods:

  • The abstract suggests the current advancements in thrombin generation assays.

Related Experiment Videos

  • It implies a review or discussion of existing methodologies.
  • Focuses on the applicability of thrombin generation measurements in clinical settings.

    • Main Results:

    • Thrombin generation assays are presented as a viable solution for current clinical needs.
    • The technology is deemed ready for application in defining therapeutic strategies.
    • Potential to dissect treatment effects and differentiate therapies is indicated.

    Conclusions:

    • The current state of thrombin generation technology is adequate to meet the need for better diagnostic and therapeutic guidance in clotting and bleeding disorders.
    • Implementing thrombin generation testing can lead to more precise and safer patient management.
    • This approach promises to improve outcomes in the management of complex hemostatic conditions.